Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Diagnostics Company Provides Clinical Interpretation of Genomics Data

By LabMedica International staff writers
Posted on 30 Jan 2013
A diagnostics company was launched to provide rapid, accurate, and turnkey clinical interpretation of genomics data at the point-of-care (POC). More...
The next phase of genomics-based medicine will provide clinicians with the tools they need to make faster, more precise and cost-saving decisions.

SV Bio’s (Foster City, CA, USA) turnkey genomics interpretation services query the patient’s genome at the POC and provide the biologic data in a concise, actionable report that medical generalists and specialists can easily use as a decision support tool. The platform fits into current clinical workflows and is able to take data from any next generation sequencer and determine, with clinical grade sensitivity and specificity, which genetic variants within a patient’s DNA sequence are influencing a disease or condition.

Many patients have already been helped by SV Bio diagnostic services. One case involved a family with two affected children who were initially thought to have autism spectrum disorder due to their language regression, IQ drops, and seizures at two years of age. Subsequent neurodegenerative decline puzzled physicians at leading medical institutions, and triggered a multiyear odyssey of clinical workups and focused genetic testing. Ultimately, the physicians turned to SV Bio, where the patient genomes were sequenced and the underlying genetic mutation in a gene named TPP1 was uncovered immediately.

The gene defect causes the rare disease late-infantile neuronal ceroid lipofuscinosis that is fatal by 8 years of age. The mutation was verified biochemically to be causative of the disorder, and allowed the children to gain access to a clinical trial that has shown promising results at halting the progression of the disease—a trial to which they would never have turned for a solution to a fatal disease in the absence of a specific molecular diagnosis.

“The transition is occurring very rapidly nowadays from genomics as a science to genomics as a key driver of clinical medicine and decision-making at the bedside,” noted Dietrich Stephan, PhD, SV Bio founder and CEO.

SV Bio is currently providing diagnostic testing services to physicians and centers of excellence for all heritable genetic conditions. These services include testing single genes and bundled gene sets for disorders that are genetically heterogeneous and for which the causative genes are known. In addition, testing of the entire genome is available for mystery illnesses or in cases where other diagnostic companies could not return a definitive result because the causative gene is not known, or in cases where a variant was detected but could not be classified as causative. SV Bio uses classification technology that provides precision of pathogenicity prediction for variants not been seen before—increasing sensitivity when coupled with the highest quality next-generation
sequencing of the entire genome.

Related Links:
SV Bio


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.